FDA approves under-the-skin Vyvgart Hytrulo to treat gMG
Note: This story was updated June 28, 2023, to correct the time frame of the ADAPT-SC+ clinical trial, in…
Articles by Marta Figueiredo, PhD
Restoring Function of Immune Cell Type May Aid in gMG Remission
Generalized myasthenia gravis (gMG) may be associated with a deficiency in a type of immune cell called myeloid-derived suppressor…
CAR T-cell Therapy Descartes-08 Continues to Show Promise in Trial
Descartes-08, Cartesian Therapeutics’ investigational CAR T-cell therapy, appears generally safe and markedly lessened symptom severity in the first five…
Phase 3 Trials to Support Requests for Two New gMG Therapies, UCB Says
Both zilucoplan and rozanolixizumab, UCB’s experimental therapies for generalized myasthenia gravis (gMG), safely and effectively reduced symptom…
Anti-thyroid Antibodies Tied to Specific Immune Profile in MG
Myasthenia gravis (MG) patients with antibodies against the thyroid gland have significantly more B-cells — the immune cells that…
Chinese Medicine May Ease MG by Acting On Gut Microbiota
Fufang Huangqi decoction — a traditional Chinese medicine formula reported to reduce symptoms of myasthenia gravis (MG) — helps…
Reduced Mitochondria Proteins May Serve as Diagnostic Biomarker of MG
The dynamics of mitochondria — the cells’ powerhouses — and their associated energy metabolism are highly affected in people with…
Late-onset MG Tied to Poor Memory, Brain Shrinkage in Small Study
Men with late-onset myasthenia gravis (MG) show poorer memory and spatial orientation, as well as lower-than-normal volumes of brain…
Redesigned Patient Website Launched by Janssen for Its US Campaign
To celebrate Rare Disease Day, on Feb. 28, Janssen has launched a refreshed national campaign, called iMaGineMyMG, to increase…
Zilucoplan Safely Reduced gMG Symptoms in Phase 3 Trial
Zilucoplan, UCB’s experimental therapy, safely and effectively eases symptom severity and improves the quality of life for adults with…